Biomarkers of vascular calcification and mortality in patients with ESRD
- PMID: 24458076
- PMCID: PMC3974354
- DOI: 10.2215/CJN.05450513
Biomarkers of vascular calcification and mortality in patients with ESRD
Abstract
Background: Vascular calcification is common among patients undergoing dialysis and is associated with mortality. Factors such as osteoprotegerin (OPG), osteopontin (OPN), bone morphogenic protein-7 (BMP-7), and fetuin-A are involved in vascular calcification.
Design, setting, participants, & measurements: OPG, OPN, BMP-7, and fetuin-A were measured in blood samples from 602 incident dialysis patients recruited from United States dialysis centers between 1995 and 1998 as part of the Choices for Healthy Outcomes In Caring for ESRD Study. Their association with all-cause and cardiovascular mortality were assessed using Cox proportional hazards models adjusted for demographic characteristics, comorbidity, serum phosphate, and calcium. An interaction with diabetes was tested because of its known association with vascular calcification. Predictive accuracy of selected biomarkers was explored by C-statistics in nested models with training and validation subcohorts.
Results: Higher OPG and lower fetuin-A levels were associated with higher mortality over up to 13 years of follow-up (median, 3.4 years). The adjusted hazard ratios (HR) for highest versus lowest tertile were 1.49 (95% confidence interval [95% CI], 1.08 to 2.06) for OPG and 0.69 (95% CI, 0.52 to 0.92) for fetuin-A. In stratified models, the highest tertile of OPG was associated with higher mortality among patients without diabetes (HR, 2.42; 95% CI, 1.35 to 4.34), but not patients with diabetes (HR, 1.26; 95% CI, 0.82 to 1.93; P for interaction=0.001). In terms of cardiovascular mortality, higher fetuin-A was associated with lower risk (HR, 0.85 per 0.1 g/L: 95% CI, 0.75 to 0.96). In patients without diabetes, higher OPG was associated with greater risk (HR for highest versus lowest tertile, 2.91; 95% CI, 1.06 to 7.99), but not in patients with diabetes or overall. OPN and BMP-7 were not independently associated with outcomes overall. The addition of OPG and fetuin-A did not significantly improve predictive accuracy of mortality.
Conclusions: OPG and fetuin-A may be risk factors for all-cause and cardiovascular mortality in patients undergoing dialysis, but do not improve risk prediction.
Keywords: diabetes; end-stage renal disease; vascular calcification.
Figures

Similar articles
-
Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.BMC Nephrol. 2017 Sep 7;18(1):290. doi: 10.1186/s12882-017-0701-8. BMC Nephrol. 2017. PMID: 28882110 Free PMC article.
-
Vascular Calcification Markers and Hemodialysis Vascular Access Complications.Am J Nephrol. 2018;48(5):330-338. doi: 10.1159/000493549. Epub 2018 Oct 31. Am J Nephrol. 2018. PMID: 30380526
-
Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.Korean J Intern Med. 2013 Nov;28(6):668-77. doi: 10.3904/kjim.2013.28.6.668. Epub 2013 Oct 29. Korean J Intern Med. 2013. PMID: 24307842 Free PMC article.
-
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Nephrol Dial Transplant. 2015 Aug;30(8):1345-56. doi: 10.1093/ndt/gfv081. Epub 2015 Apr 7. Nephrol Dial Transplant. 2015. PMID: 25854266 Review.
-
Vascular calcification biomarkers and peripheral arterial disease.Int Angiol. 2016 Oct;35(5):455-9. Epub 2015 Jun 5. Int Angiol. 2016. PMID: 26044839 Review.
Cited by
-
Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients.Front Med (Lausanne). 2022 Jun 22;9:814970. doi: 10.3389/fmed.2022.814970. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35814784 Free PMC article.
-
Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice.J Mol Med (Berl). 2016 Jan;94(1):95-106. doi: 10.1007/s00109-015-1331-x. Epub 2015 Aug 27. J Mol Med (Berl). 2016. PMID: 26307633
-
Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis.Clujul Med. 2016;89(1):94-103. doi: 10.15386/cjmed-515. Epub 2016 Jan 15. Clujul Med. 2016. PMID: 27004031 Free PMC article.
-
Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.BMC Nephrol. 2017 Sep 7;18(1):290. doi: 10.1186/s12882-017-0701-8. BMC Nephrol. 2017. PMID: 28882110 Free PMC article.
-
The role of fetuin-A in mineral trafficking and deposition.Bonekey Rep. 2015 May 6;4:672. doi: 10.1038/bonekey.2015.39. eCollection 2015. Bonekey Rep. 2015. PMID: 25987986 Free PMC article. Review.
References
-
- United States Renal Data System : USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
-
- Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R, 3rd: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790–796, 1979 - PubMed
-
- Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478–1483, 2000 - PubMed
-
- Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453–1464, 2009 - PubMed
-
- Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19: 213–216, 2008 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 5R01DK072367-03/DK/NIDDK NIH HHS/United States
- R01DK080123/DK/NIDDK NIH HHS/United States
- K23 DK083514/DK/NIDDK NIH HHS/United States
- K24 DK002643/DK/NIDDK NIH HHS/United States
- K23DK083514/DK/NIDDK NIH HHS/United States
- 5KL2RR025006/RR/NCRR NIH HHS/United States
- R01 HL062985/HL/NHLBI NIH HHS/United States
- R01 DK059616/DK/NIDDK NIH HHS/United States
- R01DK059616/DK/NIDDK NIH HHS/United States
- R01HL62985/HL/NHLBI NIH HHS/United States
- 5K01DK067207-05/DK/NIDDK NIH HHS/United States
- U01 DK070657/DK/NIDDK NIH HHS/United States
- R01HS008365/HS/AHRQ HHS/United States
- K01 DK067207/DK/NIDDK NIH HHS/United States
- 5U01DK070657-03/DK/NIDDK NIH HHS/United States
- R01 DK080123/DK/NIDDK NIH HHS/United States
- T32 DK007732/DK/NIDDK NIH HHS/United States
- KL2 RR025006/RR/NCRR NIH HHS/United States
- K23 DK095949/DK/NIDDK NIH HHS/United States
- K24DK02643/DK/NIDDK NIH HHS/United States
- T32DK007732-14/DK/NIDDK NIH HHS/United States
- R01 DK072367/DK/NIDDK NIH HHS/United States
- R01 HS008365/HS/AHRQ HHS/United States
- K23DK095949/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous